ArticleJournal, genetic engineering & biotechnology2025
Influence of growth factors and different supplements on metabolic response and productivity of IgA-producing CHO cell lines.
Article in Journal, genetic engineering & biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
IgA antibodies have great potential for use in novel cancer immunotherapy based on recombinant monoclonal antibodies. This antitumor application is related to the effector functions of IgA. IgA subisotypes have special effector function features explained by a more complex glycosylation process compared to IgG antibodies. Studying of interrelations of metabolites, glucose consumptions, cell growth and antibody production can allow to get better control of antibody glycosylation and product quality. Reducing of metabolites in culture have influence on productivity and probably on glycosylation and can be achieved through process optimization or metabolic engineering. IgA1 and IgA2m1 have different effector functions associated with distinct glycosylation profiles. The aim of our study was to evaluate the effect of human growth factors such as hNGF, hEGF, and FGF-b combined with some supplements on metabolic level and production of recombinant IgA antibodies. The results demonstrated that combination growth factors and succinic acid improves metabolism of CHO cells producing recombinant monoclonal antibody IgA isotype, especially for IgA2m1producing cell line. These results suggest that combining hNGF, hEGF, and succinic acid supplementation has the potential to be used as effective additives to cell media for increasing the cell culture density, and optimization of IgA1-IgA2 cell line productivity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.